Prestige Consumer Healthcare (($PBH)) has held its Q4 earnings call. Read on for the main highlights of the call.
Prestige Consumer Healthcare’s latest earnings call struck a cautious but constructive tone as management balanced solid cash generation and resilient margins against clear near-term execution risks. Investors were reminded that Clear Eyes supply disruptions, shipping issues tied to geopolitical events, and integration of recent deals will pressure results in fiscal 2027, even as management argues these moves set up a stronger growth profile beyond the next year.
Robust Free Cash Flow Underpins Financial Flexibility
Prestige generated $246.4 million of free cash flow in fiscal 2026, a roughly 1.3% increase despite top-line pressure and operational disruptions. Management expects at least $250 million in free cash flow for fiscal 2027 and projects cumulative cash generation approaching $900 million over the next three years, excluding pending acquisitions, reinforcing the balance sheet’s support for both investment and returns.
Disciplined Capital Allocation and Shareholder Returns
The company emphasized a disciplined capital allocation framework after repurchasing more than $150 million of stock in fiscal 2026 and investing about $110 million to acquire Pillar5 and secure eye care manufacturing. With over $90 million of repurchase authorization remaining, Prestige plans to prioritize spending behind key brands, debt reduction, and selective M&A, positioning shareholders to benefit from both growth and deleveraging.
Margins Hold Firm Amid Revenue Headwinds
Adjusted gross margin came in at 55.6% for fiscal 2026, essentially flat versus the prior year’s 55.8%, underscoring pricing power and cost discipline. Despite sales declines and supply chain challenges, Prestige maintained a low-30s EBITDA margin profile, signaling that profitability remains resilient even in a more volatile operating environment.
Strategic Acquisitions Expand Platform
Prestige continued to build its portfolio with the acquisition of Pillar5 in December to internalize eye care production and reduce reliance on third parties. It also announced pending deals for Breathe Right, expected to contribute more than $125 million of revenue, and LaCorium, projected at around $40 million of revenue, with management noting that Breathe Right should be meaningfully accretive to earnings while LaCorium is expected to be neutral to slightly accretive.
E-Commerce Momentum and Brand Strength
Digital channels remain a bright spot, with e-commerce penetration reaching about 18% and continuing to grow at a double-digit pace, supporting the company’s omnichannel strategy. Management highlighted leading franchises such as Fleet, which holds more than 50% market share, growing GI brands, stabilized trends in Summer’s Eve, and Monistat maintaining share despite broader category softness.
Initial Fiscal 2027 Outlook Stays Cautious
For fiscal 2027, Prestige guided revenue to a range of $1.10 billion to $1.12 billion, implying organic growth of roughly 1% to 3% as supply constraints gradually ease. Adjusted EPS is expected between $4.42 and $4.51, with first-quarter revenue around $250 million and EPS near $0.87, while gross margins should remain roughly in line with fiscal 2026 levels.
Low Capital Spending Supports Cash Conversion
The company reiterated that its asset-light model requires modest capital investment, keeping capex at about 1% to 3% of sales. Even after incorporating Pillar5, Prestige expects to spend roughly $25 million on capex in fiscal 2027, which supports strong free cash flow conversion and preserves optionality for debt paydown and future deals.
Medium-Term Growth Ambitions Remain Intact
Looking beyond the current disruptions, management outlined a medium-term plan targeting a revenue CAGR approaching 10% through fiscal 2029, driven by acquisitions, recovery in eye care, and expanding international reach. EPS is expected to grow at 8% or more over the same period, with international sales potentially approaching 20% of the total, underpinned by sustained low-to-mid-30s EBITDA margins.
Clear Eyes Supply Chain Challenges Weigh on Results
The company acknowledged that Clear Eyes was a primary drag on fiscal 2026 performance after production shutdowns, delayed shipments, and extended maintenance downtime at Pillar5. These issues have spilled into fiscal 2027 and are driving near-term volatility, although management believes that the investment in internal manufacturing will ultimately stabilize supply and support future growth.
Revenue Declines Reflect Operational and External Pressures
Fourth-quarter revenue fell to $281.6 million, a roughly 5% decline year over year, or 6.4% excluding foreign exchange, while full-year fiscal 2026 revenue declined about 4% and 4.5% organically. Management noted that top-line softness was concentrated in eye care and specific international markets, with underlying demand for many core brands showing greater stability than the headline numbers suggest.
Explaining the Quarterly Guidance Miss
Prestige attributed roughly $12 million of the fourth-quarter shortfall versus guidance primarily to operational disruptions in eye care and geopolitical impacts on shipping. About two-thirds of the miss was tied to supply issues in the eye care portfolio, while the remaining third stemmed from Middle East shipping disruptions and the lap of a prior-year e-commerce timing benefit of around $7 million.
Profitability Hit by Lower Sales and Margin Pressure
Adjusted EPS declined to $4.38 from $4.52 in the prior year, a drop of about $0.14, reflecting the impact of lower revenue and some gross margin pressure. In the fourth quarter, adjusted EBITDA and EPS both fell by high single digits as supply disruptions and mix weighed on profitability despite cost savings elsewhere in the business.
Geopolitical Disruptions Impact International Business
The conflict in the Middle East created shipment timing issues and longer lead times for distributors, contributing to a 2.8% decline in international OTC sales for fiscal 2026 on a constant-currency basis. Management warned that these logistical challenges will continue to weigh on international results into the first quarter of fiscal 2027, even as they work to reroute and diversify shipping lanes.
Near-Term Volatility and Operational Risk Persist
Management cautioned investors to expect period-to-period volatility as Pillar5 ramps production and Clear Eyes inventory normalizes, particularly in the first half of fiscal 2027. The company anticipates most of the improvement in eye care supply will occur in the back half of the year, implying a more back-end-loaded growth profile and elevated operational risk until the new manufacturing setup is fully stabilized.
Higher G&A and Financing Needs in the Short Term
Adjusted G&A is forecast to rise to about 10.5% of sales in fiscal 2027, reflecting the inclusion of Pillar5 and normalized incentive compensation, with first-quarter G&A around $30 million. The pending acquisitions will be funded with new term loan debt, temporarily increasing leverage before a planned deleveraging phase, and management is balancing this with continued share repurchases and investment in marketing.
Conservative Guidance Reflects Uncertain Environment
Prestige’s fiscal 2027 guidance embeds organic growth of roughly 1% to 3% and largely flat gross margin, signaling a modest near-term recovery rather than a sharp rebound. Management widened the guidance range to account for uncertainty around supply timing, consumer demand, and external cost pressures, framing the year as a transition toward a more robust growth phase from fiscal 2028 onward.
Forward-Looking Guidance and Strategic Outlook
The company’s formal outlook for fiscal 2027 calls for revenues of $1.10 billion to $1.12 billion, adjusted EPS between $4.42 and $4.51, and free cash flow of $250 million or more, supported by capex of about $25 million. Over the longer term, Prestige aims to sustain low-to-mid-30s EBITDA margins, deliver an EPS CAGR of at least 8% through fiscal 2029, and use cumulative cash flow of around $900 million to fund acquisitions, reduce leverage toward roughly 3x, and support ongoing share repurchases.
Prestige Consumer Healthcare’s earnings call painted a picture of a company navigating short-term turbulence while laying groundwork for stronger, acquisition-fueled growth. Investors must weigh near-term execution risk, particularly around Clear Eyes and international logistics, against the firm’s strong cash generation, resilient margins, and clear strategy for building a larger, more globally diversified consumer health platform.
